Seeking Alpha EN

Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data

Mar 24, 2026 &03312424202631; 14:31 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -35/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Goldman Sachs downgraded Ultragenyx (RARE) to neutral citing setrusumab data concerns. The news is 43 minutes old and the stock has likely already absorbed the initial reaction; broader market shows minimal movement with S&P 500 flat and VIX slightly elevated.

AI CONFIDENCE

42% Moderate

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

RARE

RAREStock

High volatility expected

Downgrade from GS is negative catalyst, but 43-minute delay means initial market reaction has likely occurred. Further downside possible if institutional selling continues, but entry point is unclear and risk/reward is poor.

⇅

S&P 500

^GSPCIndex

High volatility expected

Biotech-specific news; S&P 500 showing minimal reaction (-0.07%). No systemic risk signal.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

SKIP THIS TRADE. The downgrade is old news and likely already priced into RARE. Without real-time order flow or knowing current RARE price vs. pre-downgrade levels, the risk/reward is unfavorable. Wait for fresh catalysts or a stabilization pattern before entering. [PRICED_IN] [MOVE:0.8%]

KEY SIGNALS

Analyst downgrade (GS neutral)Setrusumab efficacy/safety concerns43-minute delay = stale newsBroad market unaffected (S&P flat)VIX uptick modest (+0.46%)

SECTORS INVOLVED

HealthcareBiotechnology

Analysis generated on Mar 24, 2026 at 15:15 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data

RELATED INTELLIGENCE